Active Biotech Interim Report Q1 2022 : vimarsana.com

FIRST QUARTER IN BRIEF Dr. Erik Vahtola appointed Chief Medical Officer First patient dosed in the combination part of the phase Ib/IIa study of tasquinimod in multiple myeloma Active Biotech...

Related Keywords

Hans Kolam , Erik Vahtola , Loncode Institute , Eu Press , Chief Medical Officer ,